ClinicalTrials.gg

Program

gadoterate meglumine

Also written as “Dotarem”, “Gadoterate meglumine (Dotarem)” and “Gadoterate meglumine”.

Its studies are mostly in Carcinoma, Hepatocellular · Central Nervous System Diseases · Brain Neoplasms · Kidney Diseases · Renal Artery Obstruction, led by Guerbet.

Furthest: phase 4, since Mar 4, 200812 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guerbet121 open or runningphase 4since Mar 4, 2008Mar 4, 2008Dec 31, 2027phase 3 · NCT07348640

Also a collaborator on its studies: Bracco Imaging.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2008First study: phase 4 study in Renal InsufficiencyFirst studyNCT00650845 · 135 enrolled · Belgium, France, Italy and more
  2. Feb 16, 2009Phase 3 study in Renal Artery ObstructionNCT00845702 · 33 enrolled · United States
  3. Sep 17, 2009Phase 3 study in Kidney DiseasesNCT00980681 · 13 enrolled · United States
  4. Nov 9, 20092 phase 3 studies in Cerebral Arterial DiseasesNCT01010932, NCT01012674
  5. Dec 3, 2009Phase 4 study in Peripheral Arterial DiseaseNCT01026389 · 189 enrolled · Austria
  6. Sep 28, 2010Phase 3 study in Central Nervous System DiseasesNCT01211873 · 416 enrolled · United States, Argentina, Austria and more
  7. Oct 3, 2011Phase 1 study in Kidney Failure, ChronicNCT01449266 · 10 enrolled · Belgium
  8. Nov 6, 2012Phase 4 study in Carcinoma, HepatocellularNCT01806740 · 37 enrolled · Korea, Republic of
  9. Jan 10, 2014Phase 4 study in Brain NeoplasmsNCT02034708 · 279 enrolled · United States, Colombia, Korea, Republic of and more
  10. Mar 11, 2015Phase 4 study in Magnetic Resonance ImagingNCT02411201 · 51 enrolled · Austria, France, Hungary and more
  11. Jan 15, 2026Phase 3 study in Steno-occlusive DiseaseNCT07348640 · 315 planned · United States, Canada, Czechia and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Steno-occlusive DiseaseNCT07348640

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07348640Steno-occlusive Disease · United States, Canada, Czechia and more3RecruitingDec 31, 2027315
NCT02411201Magnetic Resonance Imaging · Austria, France, Hungary and more4CompletedOct 201551
NCT02034708Brain Neoplasms · United States, Colombia, Korea, Republic of and more4CompletedSep 2015279
NCT01806740Carcinoma, Hepatocellular · Korea, Republic of4TerminatedOct 12, 201537
NCT01449266Kidney Failure, Chronic · Belgium1CompletedMar 201210
NCT01211873Central Nervous System Diseases · United States, Argentina, Austria and more3CompletedNov 2011416
NCT01026389Peripheral Arterial Disease · Austria4CompletedJun 2011189
NCT01012674Cerebral Arterial Diseases · United States3CompletedDec 2010211
NCT01010932Cerebral Arterial Diseases · United States3CompletedDec 2010222
NCT00980681Kidney Diseases · United States3TerminatedDec 201013
NCT00845702Renal Artery Obstruction · United States3TerminatedFeb 201033
NCT00650845Renal Insufficiency · Belgium, France, Italy and more4CompletedMay 2011135

How it is read

Names in the registry

  • “Dotarem”, 4 entries
  • “Gadoterate meglumine (Dotarem)”, 2 entries
  • “Gadoterate meglumine”, 1 entry
  • “Dotarem (gadoterate meglumine)”, 1 entry
  • “DOTAREM”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
gadoterate meglumine (Guerbet): development program | ClinicalTrials.gg